Clinical Trials Using Eribulin Mesylate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Eribulin Mesylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-17 of 17
  • Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients with Recurrent Stage IIIC-IV Breast Cancer

    This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back. Drugs used in chemotherapy, such as eribulin mesylate and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 36 locations

  • Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

    The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy.
    Location: 14 locations

  • A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).
    Location: 11 locations

  • Eribulin Mesylate in Treating Patients with Previously Treated Metastatic Breast Cancer

    This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 9 locations

  • Selinexor with Multiple Standard Chemotherapy Regimens in Treating Patients with Advanced Malignancies

    This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Studying selinexor with different standard chemotherapy regimens may help doctors learn the side effects and best dose of selinexor that can be given with different types of treatments in one study.
    Location: 5 locations

  • Eribulin Mesylate with or without Pembrolizumab in Treating Patients with Hormone Receptor Positive and HER2 Negative Stage IV Breast Cancer

    This randomized phase II trial studies how well eribulin mesylate with or without pembrolizumab works in treating patients with hormone receptor positive and HER2 negative stage IV breast cancer. Eribulin mesylate may prevent tumor cells from multiplying. Monoclonal antibodies, such as pembrolizumab, may help the immune system attack tumor cells. Giving eribulin mesylate with pembrolizumab may work better in patients with stage IV breast cancer.
    Location: 4 locations

  • Eribulin Mesylate Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with HER2-Negative Inflammatory Breast Cancer before Surgery

    This phase II trial studies how well eribulin mesylate works in combination with doxorubicin hydrochloride and cyclophosphamide in treating patients with human epidermal growth factor receptor 2 (HER2)-negative inflammatory breast cancer before surgery. Eribulin mesylate works by interfering with cancer cell division, growth, and spread. Drugs used in chemotherapy, such as doxorubicin hydrochloride and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving eribulin mesylate together with doxorubicin hydrochloride and cyclophosphamide before surgery may be an effective treatment in HER2-negative inflammatory breast cancer patients.
    Location: 3 locations

  • Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)

    This is an open-label, single-arm, multicenter, Phase 1b / 2 study of eribulin mesylate in combination with pembrolizumab in participants with metastatic triple-negative breast cancer (mTNBC) previously treated with 0 to 2 lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
    Location: 3 locations

  • Eribulin Mesylate in Treating Patients with Brain Metastases from Breast Cancer

    This phase II trial studies how well eribulin mesylate works in treating patients with breast cancer that has spread to the brain. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 2 locations

  • Eribulin Mesylate and Irinotecan Hydrochloride in Treating Adolescent and Young Adult Patients with Relapsed or Refractory Solid Tumors

    This phase I / Ib trial studies the side effects and best dose of eribulin mesylate when given together with irinotecan hydrochloride in treating adolescent and young adults with solid tumors that are no longer responding to treatment or have spread to other places in the body. Eribulin mesylate may stop the growth of tumor cells by blocking microtubules needed for cell growth. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving eribulin mesylate and irinotecan hydrochloride may work better in treating patients with relapsed or refractory solid tumors.
    Location: 2 locations

  • Eribulin Mesylate and Everolimus in Treating Patients with Triple-Negative Metastatic Breast Cancer

    This phase I / Ib trial studies the side effects and best dose of eribulin mesylate and everolimus in treating patients with breast cancer that does not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 protein (triple-negative) and has spread to other places in the body (metastatic). Eribulin mesylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Rebastinib Tosylate and Paclitaxel or Eribuilin Mesylate in Treating Patients with HER2 Negative Metastatic Breast Cancer

    This phase Ib trial studies the best dose and side effects of rebastinib tosylate when given together with paclitaxel or eribulin mesylate in treating patients with HER2 negative breast cancer that has spread to other parts of the body. Rebastinib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rebastinib tosylate with paclitaxel or eribulin may work better in treating patients with breast cancer.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • Eribulin Mesylate and Lenvatinib Mesylate in Treating Patients with Stage IV Breast Cancer, Non-Small Cell Lung Cancer, or Sarcoma

    This phase II trial studies the side effects of eribulin mesylate and lenvatinib mesylate and how well they work in treating patients with stage IV breast cancer, non-small cell lung cancer, or sarcoma. Eribulin mesylate and lenvatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer

    This phase II trial studies how well eribulin mesylate works in treating patients with cervical cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has come back (recurrent). Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Eribulin Mesylate and Cyclophosphamide in Treating Patients With Solid Tumor Malignancies

    The purpose of this study is to test the safety of eribulin (eribulin mesylate) (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. We want to find out what effects, good and / or bad, these drugs have on you and your cancer. Eribulin is a drug that has been approved by the U.S. Food and Drug Administration (FDA) for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is considered experimental; that means this combination has not been approved by the FDA.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • ASCENT-Study of Sacituzumab Govitecan in Refractory / Relapsed Triple-Negative Breast Cancer

    This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC), which needs to be selected prior to randomization from one of the 4 allowed regimens. Randomization will be stratified by number of prior chemotherapies for advanced disease (2-3 vs > 3) and geographical location (North America vs Europe). Patients will be treated until progression, unacceptable toxicity, study withdrawal, or death, whichever comes first. Tumor progression leading to treatment withdrawal will be assessed by the investigator. Starting with the initial dose of sacituzumab govitecan or TPC, CT scans (or MRI if contrast allergic) will be obtained at least every 8 weeks until the occurrence of progression of disease requiring discontinuation of further treatment.All patients, including those prematurely terminating study participation, will be followed every 4 weeks during the first year and every 8 weeks thereafter for survival follow-up.
    Location: 3 locations

  • Atezolizumab with or without Eribulin Mesylate in Treating Patients with Recurrent Locally Advanced or Metastatic Urothelial Cancer

    This randomized phase II trial studies the side effects of atezolizumab with or without eribulin mesylate and how well they work in treating patients with urothelial cancer that has come back, spread to nearby tissues and lymph nodes, or other places in the body. Monoclonal antibodies, such as atezolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab and eribulin mesylate may work better at treating urothelial cancer.
    Location: City of Hope Comprehensive Cancer Center LAO, Duarte, California